Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
2021; Cell Press; Volume: 39; Issue: 8 Linguagem: Inglês
10.1016/j.ccell.2021.06.009
ISSN1878-3686
AutoresAlfredo Addeo, Pankil Shah, Natacha Bordry, Robert D. Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, Pierre-Yves Dietrich, Barbara S. Taylor, Pierre-Francois Simand, Darpan I. Patel, Jing Wang, Sana Intidhar Labidi‐Galy, Sara Fertani, Robin J. Leach, José Luís Sandoval, Ruben A. Mesa, Kate Lathrop, Nicolas Mach, Dimpy P. Shah,
Tópico(s)COVID-19 Clinical Research Studies
ResumoHighlights•mRNA vaccination produces high seroconversion in patients with cancer•Second vaccine dose is important to boost antibody levels in these patients•Non-response to vaccine was more likely in patients with hematologic malignancy•No patients on rituximab developed antibodies even after full vaccinationSummaryPatients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.Graphical abstract
Referência(s)